Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting

Basit Öğe Kaydı
dc.authoridKirkizlar, Onur/0000-0001-7523-8599
dc.authoridOksuz, Ergun/0000-0002-5723-5965
dc.authoridEskazan, Ahmet Emre/0000-0001-9568-0894
dc.authorwosidSaydam, Guray/W-3827-2017
dc.authorwosidHaznedaroglu, Ibrahim C./B-7408-2009
dc.authorwosidKirkizlar, Onur/W-9594-2018
dc.authorwosidOksuz, Ergun/K-8238-2012
dc.authorwosidEskazan, Ahmet Emre/B-8278-2015
dc.contributor.authorEskazan, Ahmet Emre
dc.contributor.authorAli, Ridvan
dc.contributor.authorAlnigenis, Ebru
dc.contributor.authorAyyildiz, Orhan
dc.contributor.authorHaznedaroglu, Ibrahim
dc.contributor.authorKirkizlar, Onur
dc.contributor.authorKurtoglu, Erdal
dc.date.accessioned2024-06-12T10:56:30Z
dc.date.available2024-06-12T10:56:30Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction The therapeutic landscape of chronic myeloid leukemia (CML) has evolved significantly since the introduction of imatinib. The European LeukemiaNet (ELN) recommendations serve as a guide for diagnosis, treatment, and monitorization of CML, but availability and accessibility of diagnostic tools and medications affect their applicability. Areas covered This article provides an overview of the current clinical management of CML in Turkey with reference to the key outputs of the online expert meeting held in November 2020. The applicability of the ELN 2020 recommendations for treating CML in clinical practice was also discussed. Expert opinion Imatinib is the only reimbursed and the most preferred first-line treatment in CML restricting the upfront use of second-generation tyrosine kinase inhibitors (TKIs), thereby limiting the applicability of treatment-free remission approach in Turkey. The ELN recommendations about using the EUTOS Long-Term Survival (ELTS) score for risk assessment and focusing on patient reported outcomes and quality of life can be enhanced with educational activities. The widespread availability of standardized technical infrastructure for diagnosing and monitoring CML will contribute to better disease management. Establishing a sustainable national database for CML is valuable for observing patient characteristics and disease outcomes as well as the impact of treatment patterns over time.en_US
dc.description.sponsorshipNovartis Pharmaceuticals Corporationen_US
dc.description.sponsorshipThe study was funded by Novartis Pharmaceuticals Corporation.en_US
dc.identifier.doi10.1080/17474086.2022.2044779
dc.identifier.endpage106en_US
dc.identifier.issn1747-4086
dc.identifier.issn1747-4094
dc.identifier.issue2en_US
dc.identifier.pmid35184657en_US
dc.identifier.scopus2-s2.0-85126047046en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage97en_US
dc.identifier.urihttps://doi.org/10.1080/17474086.2022.2044779
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19804
dc.identifier.volume15en_US
dc.identifier.wosWOS:000764920100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Review Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Myeloid Leukemiaen_US
dc.subjectCMLen_US
dc.subjectComorbiditiesen_US
dc.subjectRisk Scoringen_US
dc.subjectTKIen_US
dc.subjectTyrosine Kinase Inhibitoren_US
dc.subjectTFRen_US
dc.subjectTreatment-Free Remissionen_US
dc.subjectGeneric Imatiniben_US
dc.subjectCml Patientsen_US
dc.subjectSurvivalen_US
dc.subjectEfficacyen_US
dc.subjectDiseaseen_US
dc.subjectSafetyen_US
dc.subjectRecommendationsen_US
dc.subjectProgressionen_US
dc.subjectTherapyen_US
dc.subjectImpacten_US
dc.titlePatient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meetingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu